超連結 .
超連結 .
In general, this study reveals the mobility, volatility and plasticity of biological age in humans and mice, challenging the long-standing concept of one-way rise in biological age. It clarifies the triggers that can cause biological age change. Exposure to stress will increase biological age. When stress is relieved, biological age can be completely Or partial recovery. These findings suggest that severe stress may increase mortality by increasing biological age, so mortality can be reduced by reducing biological age, and being able to recover from stress may be an important determinant for anti-aging.
2023年 4月21日來自哈佛醫學院的 Vadim N. Gladyshev 聯合杜克學醫學院的 James P. White 在 Cell Metabolism上發表, 作者利用DNA甲基化（DNAm）時鐘評估人類和小鼠的生物年齡，首次揭示了人類和小鼠的生物年齡不是靜態或穩定的增長，而是在受到壓力後短時間內發生可逆性的變化。
On April 21, 2023, Gladyshev's research group from Harvard Med and JP White's research group from Duke published the article. The authors used the DNA methylation (DNAm) clock to assess the biological age of humans and mice, revealing for the first time that the biological age of humans and mice is not a static or steady increase, but a reversible change in a short period of time after being stressed.
Cell Metab 2023 Apr 4;S1550-4131(23)00093-1. doi: 10.1016/j.cmet.2023.03.015. Online ahead of print.https://doi.org/10.1016/j.cmet.2023.03.015
In general, this study reveals the mobility, volatility and plasticity of biological age in humans and mice, challenging the long-standing concept of one-way rise in biological age. It clarifies the triggers that can cause biological age change. Exposure to stress will increase biological age. When stress is relieved, biological age can be completely Or partial recovery. These findings suggest that severe stress may increase mortality by increasing biological age, so mortality can be reduced by reducing biological age, and being able to recover from stress may be an important determinant for anti-aging.
2023年 4月21日來自哈佛醫學院的 Vadim N. Gladyshev 聯合杜克學醫學院的 James P. White 在 Cell Metabolism上發表, 作者利用DNA甲基化（DNAm）時鐘評估人類和小鼠的生物年齡，首次揭示了人類和小鼠的生物年齡不是靜態或穩定的增長，而是在受到壓力後短時間內發生可逆性的變化。
On April 21, 2023, Gladyshev's research group from Harvard Med and JP White's research group from Duke published the article. The authors used the DNA methylation (DNAm) clock to assess the biological age of humans and mice, revealing for the first time that the biological age of humans and mice is not a static or steady increase, but a reversible change in a short period of time after being stressed.
Cell Metab 2023 Apr 4;S1550-4131(23)00093-1. doi: 10.1016/j.cmet.2023.03.015. Online ahead of print.https://doi.org/10.1016/j.cmet.2023.03.015
Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2213120119. doi: 10.1073/pnas.2213120119.
On April 28, 2022, Eli Lilly and Company of the United States officially announced that a new drug developed by it, Tirzepatide (Tirzepatide), has completed Phase 3 clinical trials and achieved the most amazing weight loss effect ever-during the 72-week study, it was able to Subtract the subject's weight of nearly 50 catties (about 22.5% of the total body weight). On July 21, 2022, the results of the Phase 3 clinical study of tesiparatide were officially published in the "New England Journal of Medicine" to fully disclose this Information on historical clinical studies
[1] https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-delivered-225-weight-loss-adults-obesity-or
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054964/
[4] https://www.thelancet.com/journals/landia/article/PIIS2213-8587(18)30024-X/fulltext
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
[6] https://pubmed.ncbi.nlm.nih.gov/18931095/
[7] https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61375-1/fulltext
[8] https://www.nejm.org/doi/full/10.1056/nejmoa1411892
[9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308305/
[10] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318231/
[11] https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14496
[12] https://onlinelibrary.wiley.com/doi/pdf/10.1038/oby.2008.231
[13] https://www.americanobesity.org/irsObesity.htm
[14] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988332/
[15] https://www.cdc.gov/nchs/fastats/obesity-overweight.htm
[16] https://www.chinacdc.cn/gwxx/202106/t20210608_231224.html
[17] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879283/
[18] https://www.cdc.gov/chronicdisease/about/costs/index.htm
[19] https://www.nature.com/articles/s41573-021-00337-8
[1] Centers for Disease Control and Prevention. (2015). Nearly half a million Americans suffered from clostridium difficile infections in a single year.
[2] Singh, T., Bedi, P., Bumrah, K., Singh, J., Rai, M., & Seelam, S. (2019). Updates in Treatment of Recurrent Clostridium difficile Infection. Journal of Clinical Medicine Research, 11(7), 465–471.
[3] EISEMAN, B., SILEN, W., BASCOM, G. S., & KAUVAR, A. J. (1958). Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery, 44(5), 854–859.
[4] Schwan, A., Sjölin, S., Trottestam, U., & Aronsson, B. (1983).Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet (London, England), 2(8354), 845.
[5] Baunwall, S. M. D., Lee, M. M., Eriksen, M. K., Mullish, B. H., Marchesi, J. R., Dahlerup, J. F., & Hvas, C. L. (2020). Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine, 29-30, 100642–100642.
[6] Van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F., Tijssen, J. G., Speelman, P., Dijkgraaf, M. G., & Keller, J. J. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. The New England journal of medicine, 368(5), 407–415.
[7] Mole, B. (2013). FDA gets to grips with faeces. Nature (London), 498(7453), 147–148.
[8] Khanna, S., Assi, M., Lee, C., Yoho, D., Louie, T., Knapple, W., Aguilar, H., Garcia-Diaz, J., Wang, G. P., Berry, S. M., Marion, J., Su, X., Braun, T., Bancke, L., & Feuerstadt, P. (2022). Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Drugs, 82(15), 1527–1538.
[9] Feuerstadt, P., Louie, T. J., Lashner, B., Wang, E. E. ., Diao, L., Bryant, J. A., Sims, M., Kraft, C. S., Cohen, S. H., Berenson, C. S., Korman, L. Y., Ford, C. B., Litcofsky, K. D., Lombardo, M.-J., Wortman, J. R., Wu, H., Auniņš, J. G., McChalicher, C. W. ., Winkler, J. A., … von Moltke, L. (2022). SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. The New England Journal of Medicine, 386(3), 220–229.
[10] Finch. (2021). Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection. https://ir.finchtherapeutics.com/news-releases/news-release-details/finch-therapeutics-announces-positive-topline-results-prism-ext/
[11] Vedanta Biosciences. (2021). Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA. https://www.vedantabio.com/news-media/press-releases/detail/2805/vedanta-announces-positive-topline-phase-2-data-for-ve303
[12] Guarner, F., & Malagelada, J. R. (2003). Gut flora in health and disease. Lancet (London, England), 361(9356), 512–519.
[13] Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., Schlitzer, A., Ginhoux, F., Apetoh, L., Chachaty, E., Woerther, P. L., Eberl, G., Bérard, M., Ecobichon, C., Clermont, D., Bizet, C., … Zitvogel, L. (2013). The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (New York, N.Y.), 342(6161), 971–976.
[14] Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., Dai, R.-M., Kiu, H., Cardone, M., Naik, S., Patri, A. K., Wang, E., Marincola, F. M., Frank, K. M., Belkaid, Y., … Goldszmid, R. S. (2013). Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment. Science (American Association for the Advancement of Science), 342(6161), 967–970.
[15] Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Lei, Y. M., Jabri, B., Alegre, M.-L., Chang, E. B., & Gajewski, T. F. (2015). Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science (American Association for the Advancement of Science), 350(6264), 1084–1089.
[16] Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., Poirier-Colame, V., Roux, A., Becharef, S., Formenti, S., Golden, E., Cording, S., Eberl, G., Schlitzer, A., Ginhoux, F., … Zitvogel, L. (2015). Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science (American Association for the Advancement of Science), 350(6264), 1079–1084.
[17] Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., Cogdill, A. P., Zhao, L., Hudgens, C. W., Hutchinson, D. S., Manzo, T., Petaccia De Macedo, M., Cotechini, T., Kumar, T., Chen, W. S., … Jiang, H. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (American Association for the Advancement of Science), 359(6371), 97–103.
[18] Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018). The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science (American Association for the Advancement of Science), 359(6371), 104–108.
[19] Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., Fidelle, M., Flament, C., Poirier-Colame, V., Opolon, P., Klein, C., Iribarren, K., Mondragón, L.,Jacquelot, N., Qu, B., Ferrere, G., … Zitvogel, L. (2018). Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science (New York, N.Y.), 359(6371), 91–97.
[20] Hayase, E., & Jenq, R. R. (2021). Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Medicine, 13(1), 107–107.
[21] World Health Organization. (2022). Autism. https://www.who.int/news-room/fact-sheets/detail/autism-spectrum-disorders
[22] Autism Speaks. (2022). Autism statistics and facts. https://www.autismspeaks.org/autism-statistics-asd
[23] Buie, T., Campbell, D. B., Fuchs, G. J., 3rd, Furuta, G. T., Levy, J., Vandewater, J., Whitaker, A. H., Atkins, D., Bauman, M. L., Beaudet, A. L., Carr, E. G., Gershon, M. D., Hyman, S. L., Jirapinyo, P., Jyonouchi, H., Kooros, K., Kushak, R., Levitt, P., Levy, S. E., Lewis, J. D., … Winter, H. (2010). Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics, 125 Suppl 1, S1–S18.
[24] Hsiao, E. Y. E. Y., McBride, S. W. S. W., Hsien, S. S., Sharon, G. G., Hyde, E. R. E. R., McCue, T. T., Codelli, J. A. J. A., Chow, J. J., Reisman, S. E. S. E., Petrosino, J. F. J. F., Patterson, P. H. P. H., & Mazmanian, S. K. S. K. (2013). The microbiota modulates gut physiology and behavioral abnormalities associated with autism. Cell, 155(7), 1451–1463.
[25] Liu, F., Li, J., Wu, F., Zheng, H., Peng, Q., & Zhou, H. (2019). Altered composition and function of intestinal microbiota in autism spectrum disorders: a systematic review. Translational Psychiatry, 9(1), 43–43.
[26] Sharon, G., Cruz, N. J., Kang, D. W., Gandal, M. J., Wang, B., Kim, Y. M., Zink, E. M., Casey, C. P., Taylor, B. C., Lane, C. J., Bramer, L. M., Isern, N. G., Hoyt, D. W., Noecker, C., Sweredoski, M. J., Moradian, A., Borenstein, E., Jansson, J. K., Knight, R., Metz, T. O., … Mazmanian, S. K. (2019). Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice. Cell, 177(6), 1600–1618.e17.
[27] Kim, S., Kim, H., Yim, Y. S., Ha, S., Atarashi, K., Tan, T. G., Longman, R. S., Honda, K., Littman, D. R., Choi, G. B., & Huh, J. R. (2017). Maternal gut bacteria promote neurodevelopmental abnormalities in mouse offspring. Nature, 549(7673), 528–532.
[28] Garcia-Gutierrez, E., Narbad, A., & Rodríguez, J. M. (2020). Autism Spectrum Disorder Associated With Gut Microbiota at Immune, Metabolomic, and Neuroactive Level. Frontiers in Neuroscience, 14, 578666–578666.
[29] Yap, C. X., Henders, A. K., Alvares, G. A., Wood, D. L. A., Krause, L., Tyson, G. W., Restuadi, R., Wallace, L., McLaren, T., Hansell, N. K., Cleary, D., Grove, R., Hafekost, C., Harun, A., Holdsworth, H., Jellett, R., Khan, F., Lawson, L. P., Leslie, J., … Gratten, J. (2021). Autism-related dietary preferences mediate autism-gut microbiome associations. Cell, 184(24), 5916–5931.e17.
[30] Kang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., Pollard, E. L., Roux, S., Sadowsky, M. J., Lipson, K. S., Sullivan, M. B., Caporaso, J. G., & Krajmalnik-Brown, R. (2017). Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: An open-label study. Microbiome, 5(1), 10–10.
[31] DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. ., Huntley, M. H., Turbett, S., Chung, R. T., Chen, Y.-B., & Hohmann, E. L. (2019). Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. The New England Journal of Medicine, 381(21), 2043–2050.
[32] U.S. FOOD & DRUG ADMINISTRATION. (2020）. Safety alert re: FMT and SARS-COV-2 and COVID-19.
[33]中國營養學會益生菌益生元與健康分會，向雪松，陳瀟.（2019）.中國批准的益生菌菌種名單. 中國科協科學傳播專家團隊.
[34] Underwood, E. (2013, December 5). Gut microbes linked to autismlike symptoms in mice. Science.
[35] Troy, E. B., & Kasper, D. L. (2010). Beneficial effects of Bacteroides fragilis polysaccharides on the immune system. Frontiers in Bioscience, 15(1), 25–34.
[36] Lee, Y. K., Mehrabian, P., Boyajian, S., Wu, W.-L., Selicha, J., Vonderfecht, S., & Mazmanian, S. K. (2018). The Protective Role of Bacteroides fragilis in Murine Model of Colitis-Associated Colorectal Cancer. mSphere, 3(6).
[37] Klarity. (2022). Our Purpose-Built Therapeutic Platform: A Unique Combination of Technologies.
[38] Switzerland, B., & Finland, K. (2022, June 15). Aurealis Therapeutics successfully completes treatment period of its phase 1 study for AUP-16 in non-healing diabetic foot ulcers: 83% patients receiving lead therapeutic dose achieved complete healing. Aurealis Therapeutics.
[39] Puurunen, M. K., Vockley, J., Searle, S. L., Sacharow, S. J., Phillips, J. A., 3rd, Denney, W. S., Goodlett, B. D., Wagner, D. A., Blankstein, L., Castillo, M. J., Charbonneau, M. R., Isabella, V. M., Sethuraman, V. V., Riese, R. J., Kurtz, C. B., & Brennan, A. M. (2021). Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nature metabolism, 3(8), 1125–1132.
A study published in the journal Nature combined the tasks of shutting your mouth and moving your legs. Leading the study are two research groups at Stanford University and Baylor College of Medicine [8]. They found that a small molecule chemical produced after strenuous exercise can effectively suppress appetite and fight obesity. The new study seeks to take a step closer to understanding the immediate effects of strenuous exercise. The researchers let the experimental mice run at high speed on the treadmill until they could not run at all, and then drew blood for mass spectrometry analysis, and found a small molecule chemical substance with a high content, which was identified as the combination of lactic acid and phenylalanine N-lactyl phenylalanine, referred to as Lac-Phe. After strenuous exercise, the Lac-Phe content in the blood increases by more than 10 times, and returns to the pre-exercise level within half an hour to 1 hour after the end of the exercise. More interestingly, the release of Lac-Phe after strenuous exercise appears to be a cross-species phenomenon. The researchers found that high levels of Lac-Phe also appeared in the blood of racehorses after strenuous running, and Lac-Phe also appeared in the blood of people after sprinting at full speed. In contrast, the increase in Lac-Phe after stretching exercises and long-distance running in people is relatively weak.
[8] https://www.nature.com/articles/s41586-022-04828-5
[9] https://link.springer.com/article/10.1007/s13679-020-00372-3
[10] https://www.pnas.org/doi/10.1073/pnas.1424638112
[11] https://science.sciencemag.org/content/369/6500/167.full
別人幫你運動竟然可以抗衰老?
[1]https://www.bmj.com/content/365/bmj.l2323
[2]https://www.who.int/dietphysicalactivity/factsheet_adults/zh/
[3]https://science.sciencemag.org/content/369/6500/167.full
[4]https://www.karger.com/Article/Abstract/210970
[5]https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.2164-0947.1972.tb02712.x
[6]https://www.businessinsider.com/young-blood-transfusions-ambrosia-shut-down-2019-6
[7]http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=24797482
[8]https://linkinghub.elsevier.com/retrieve/pii/S0092-8674(13)00456-X
[9]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497834/
[10]http://www.bioraylab.com/newsinfo/27.html
[11]https://www.clinicaltrialsarena.com/news/sangamo-gene-therapy-tdt-results/
[12] https://www.globenewswire.com/news-release/2020/06/12/2047260/0/en/CRISPR-Therapeutics-and-Vertex-Announce-New-Clinical-Data-for-Investigational-Gene-Editing-Therapy-CTX001-in-Severe-Hemoglobinopathies-at-the-25th-Annual-European-Hematology-Associ.html
[13]https://science.sciencemag.org/content/369/6501/333
[14]https://www.nature.com/articles/s41586-020-2477-4
[15]https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
[16]https://science.sciencemag.org/content/early/2020/07/16/science.abc5096
Metformin
[1]https://www.amg-ketamine.com/wp-content/uploads/2021/06/6-Antidepressant.pdf
[2]https://www.nature.com/articles/s41591-021-01336-3
[3]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985449/
[4]https://www.nejm.org/doi/full/10.1056/nejmoa2032994
[5]https://www.nature.com/articles/d41586-021-00187-9
[6]https://www.science.org/doi/10.1126/science.abl8615
[7]https://publichealth.nyu.edu/events-news/news/2021/11/05/breakthrough-xenotransplantation
[8]https://nyulangone.org/news/nyu-langone-health-performs-second-successful-xenotransplantation-surgery
[9]https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-intentional-genomic-alteration-line-domestic-pigs-both-human-food
[10]https://onlinelibrary.wiley.com/doi/10.1111/ajt.16930
[11]https://www.youtube.com/watch?v=affWrDKZ9zw
[12]https://unos.org/news/2021-all-time-records-organ-transplants-deceased-donor-donation/
[13]https://link.springer.com/article/10.1007/s12015-020-10113-7
[14]https://www.nature.com/articles/s41564-019-0469-7
[15]https://www.science.org/doi/epdf/10.1126/scitranslmed.abm7190
[16]https://www.frontiersin.org/articles/10.3389/fendo.2021.718942/full
[17]https://www.afar.org/tame-trial
[18]https://www.science.org/doi/10.1126/science.abg7292
[19]https://www.nature.com/articles/nm.4345
[20]https://www.cell.com/article/S1550-4131(14)00279-4/fulltext; https://www.nature.com/articles/nature23275;
[21]https://www.cell.com/cell-metabolism/pdfExtended/S1550-4131(16)30481-8
[22]https://www.nature.com/articles/s41586-022-04431-8